Peptide news
Curated weekly from FDA notices, manufacturer press releases, peer-reviewed studies, and trusted outlets. Direct source links on every item. Practical takeaways for users, not academic abstracts.
- Regulatorythefdalawblog.com
Riders on the Storm Part 3: Devices, Compounding, GLP-1 Medications, and Food
This is a GLP-1 compounding policy item, so the peptide angle is access and pharmacy rules rather than a new dosing protocol. If you rely on compounded GLP-1s, watch FDA and pharmacy updates before assuming the same product will stay available.
Read source → - Regulatorystatnews.com
What is pulmonary hypertension and why would a new GLP-1 help?
A GLP-1 is being discussed for pulmonary hypertension, which would push the class beyond weight loss and diabetes. Do not extrapolate this to your own plan until the actual compound, trial stage, and patient population are clear.
Read source → - Regulatorylilly.gcs-web.com
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
This is an oral GLP-1 access or trial signal around orforglipron, Lilly's non injectable GLP-1. Watch approval status, coverage rules, and full trial data before treating it like a replacement for injectable GLP-1s.
Read source → - Regulatorynews.google.com
Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program
Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program. Treat this as a regulatory signal, not a protocol change. Check whether it affects access, safety, evidence quality, or coverage before changing your plan.
Read source → - Regulatorynews.google.com
South African court grants Novo Nordisk petition to block Ozempic copies
South African court grants Novo Nordisk petition to block Ozempic copies. Treat this as a regulatory signal, not a protocol change. Check whether it affects access, safety, evidence quality, or coverage before changing your plan.
Read source → - Regulatorynews.google.com
People taking GLP-1 weight loss drugs like Ozempic started moving less
People taking GLP-1 weight loss drugs like Ozempic started moving less. Treat this as a regulatory signal, not a protocol change. Check whether it affects access, safety, evidence quality, or coverage before changing your plan.
Read source → - Regulatorylilly.gcs-web.com
Zepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
Lilly is using Zepbound (tirzepatide) to push awareness that obstructive sleep apnea can be treated, not just endured. If sleep apnea is part of your weight loss picture, watch the official indication, prescriber criteria, and insurance rules before assuming access changes.
Read source → - Regulatorynews.google.com
Drug Fights GLP-1 Muscle Loss; Unapproved Retatrutide Prescriptions; Protein Swap
Drug Fights GLP-1 Muscle Loss; Unapproved Retatrutide Prescriptions; Protein Swap. Treat this as a regulatory signal, not a protocol change. Check whether it affects access, safety, evidence quality, or coverage before changing your plan.
Read source → - Trialslilly.gcs-web.com
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
This is an oral GLP-1 access or trial signal around orforglipron, Lilly's non injectable GLP-1. Watch approval status, coverage rules, and full trial data before treating it like a replacement for injectable GLP-1s.
Read source → - Trialsnews.google.com
GLP-1, Amylin Analog Combo Cuts Blood Sugar, Weight in Diabetes Trials
GLP-1, Amylin Analog Combo Cuts Blood Sugar, Weight in Diabetes Trials. Treat this as a trials signal, not a protocol change. Check whether it affects access, safety, evidence quality, or coverage before changing your plan.
Read source → - Trialsnews.google.com
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Treat this as a trials signal, not a protocol change. Check whether it affects access, safety, evidence quality, or coverage before changing your plan.
Read source → - Trialsnews.google.com
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Treat this as a trials signal, not a protocol change. Check whether it affects access, safety, evidence quality, or coverage before changing your plan.
Read source →
Pepdex aggregates research news from primary sources only, FDA Federal Register notices, manufacturer investor releases, peer-reviewed studies on PubMed / NEJM / Lancet, and trusted outlets (BioPharma Dive, STAT, AJMC, university research pages). We summarize in plain English; you click the source link to verify. No vendor sponsorship.